livtencity
takeda pharmaceuticals international ag ireland branch - maribavir - citomegalovirusinės infekcijos - antivirusiniai vaistai sisteminiam naudojimui - livtencity is indicated for the treatment of cytomegalovirus (cmv) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (hsct) or solid organ transplant (sot). reikėtų atsižvelgti į oficialius nurodymus, kaip tinkamai naudoti antivirusinių medžiagų.
teriflunomide mylan
mylan pharmaceuticals limited - teriflunomide - išsėtinė sklerozė, grįžtamoji-pervedimo - imunosupresantai - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).
teriflunomide accord
accord healthcare s.l.u. - teriflunomide - išsėtinė sklerozė, grįžtamoji-pervedimo - imunosupresantais, pasirinktinio imunosupresantais - teriflunomide accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).
tifay
stada arzneimittel ag - teriflunomidas - plėvele dengtos tabletės - 14 mg - teriflunomide
aregalu
krka, d.d., novo mesto - teriflunomidas - plėvele dengtos tabletės - 14 mg - teriflunomide
bozilos
egis pharmaceuticals plc - teriflunomidas - plėvele dengtos tabletės - 14 mg - teriflunomide
terebyo
sandoz d.d. - teriflunomidas - plėvele dengtos tabletės - 14 mg - teriflunomide
teriflunomide zentiva
zentiva k.s. - teriflunomidas - plėvele dengtos tabletės - 14 mg - teriflunomide
boxarid
gedeon richter plc - teriflunomidas - plėvele dengtos tabletės - 14 mg - teriflunomide
tibsovo
les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - antinavikiniai vaistai - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.